Complete Filing Data
Cellyan Biotechnology Co., Ltd reported Restricted Cash And Cash Equivalents of $749.1 thousand for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cellyan Biotechnology Co., Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Selling General And Administrative Expense | $2.2M | $1.9M | $1.8M |
| Profit Loss From Operating Activities | -$2.3M | -$2.0M | -$1.8M |
| Profit Loss Before Tax | $36.1K | $1.5M | $1.0M |
| Profit Loss Attributable To Owners Of Parent | -$27.1K | $1.3M | $998.2K |
| Profit Loss | -$27.1K | $1.3M | $998.2K |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | $15.7K | -$516.00 | $640.00 |
| Other Comprehensive Income Net Of Tax Cash Flow Hedges | -$11.4K | $1.3M | $998.8K |
| Operating Profit Loss Operating | $132.0K | $1.6M | $1.0M |
| Income Tax Expense Continuing Operations | $63.2K | $196.3K | $22.6K |
| Gross Profit | $2.4M | $3.6M | $2.7M |
| Cost Of Sales | $17.9M | $13.1M | $9.8M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Restricted Cash And Cash Equivalents | $749.1K | $627.3K | $524.6K | $85.0K |
| Rightofuse Assets Obtained In Exchange For Operating New Lease Liabilities | $882.9K | $1.1M | $606.4K | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $69.9K | $52.7K | $114.6K | |
| Purchase Of Intangible Assets Classified As Investing Activities | $85.1K | $35.3K | $3.1K | |
| Cash Flows From Used In Operating Activities | $569.2K | -$394.3K | $1.7M | |
| Cash Flows From Used In Investing Activities | -$2.5M | -$40.8K | -$132.1K | |
| Cash Flows From Used In Financing Activities | $2.0M | $537.3K | -$1.2M | |
| Cash Advances And Loans From Related Parties | $819.2K | $767.8K | $189.2K | |
| Adjustments For Increase Decrease In Trade And Other Payables | $396.9K | -$105.2K | $955.3K | |
| Adjustments For Increase Decrease In Taxes Payable | -$114.9K | $196.3K | $22.6K | |
| Adjustments For Increase Decrease In Contract Liabilities | -$67.6K | -$77.8K | $210.4K | |
| Adjustments For Decrease Increase In Trade And Other Receivables | $918.8K | $2.0M | $929.5K | |
| Adjustments For Decrease Increase In Other Receivables And Prepayments | $98.2K | $44.0K | $180.4K | |
| Adjustments For Amortisation Right Of Use Assets Expense | $997.6K | $861.3K | $640.6K | |
| Trade And Other Current Receivables Due From Related Parties | $57.3K | $20.0K | ||
| Trade And Other Current Payables | $1.8M | $1.4M | ||
| Rightofuse Assets | $482.5K | $730.5K | ||
| Retained Earnings | $1.5M | $1.5M | ||
| Repayment Of Longterm Payable | $23.0K | $9.0K | ||
| Property Plant And Equipment | $111.2K | $103.2K | ||
| Noncurrent Liabilities | $1.5M | $1.2M | ||
| Noncurrent Lease Liabilities | $6.4K | $117.8K | ||
| Noncurrent Assets | $690.2K | $865.5K | ||
| Liabilities | $4.4M | $4.4M | ||
| Intangible Assets And Goodwill | $96.4K | $31.8K | ||
| Equity And Liabilities | $9.4M | $8.7M | ||
| Current Trade Receivables | $4.7M | $3.7M | ||
| Current Tax Liabilities Current | $105.1K | $218.8K | ||
| Current Restricted Cash And Cash Equivalents | $400.00 | $7.7K | ||
| Current Prepayments And Other Current Assets | $447.9K | $1.3M | ||
| Current Liabilities | $2.9M | $3.2M | ||
| Current Lease Liabilities | $493.1K | $634.5K | ||
| Current Assets | $8.7M | $7.8M | ||
| Contract Liabilities | $124.5K | $191.1K | ||
| Cash And Cash Equivalents | $748.7K | $619.6K | ||
| Assets | $9.4M | $8.7M | ||
| Amounts Payable Related Party Transactions | $1.3K | $500.7K | ||
| Accumulated Other Comprehensive Income | $10.8K | -$4.9K | ||
| Current Financial Assets At Fair Value Through Profit Or Loss | $2.3M | |||
| Rightofuse Assets And Operating Lease Liabilities Modification | -$137.1K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Payments Of Lease Liabilities Classified As Financing Activities | $1.0M | $847.9K | $612.9K |
| Increase Decrease In Cash And Cash Equivalents | $121.9K | $102.6K | $439.6K |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $12.5K | $455.00 | $321.00 |
| Proceeds From Capital Contribution From Shareholders | $300.0K | $509.5K | |
| Payments Of Deferred IPO Costs | $1.4M | $345.2K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Shares | 10.2M | 7.4M | 6.8M |
| Diluted Earnings Loss Per Share | $0.00 | $0.18 | $0.15 |
| Basic Earnings Loss Per Share | $0.00 | $0.18 | $0.15 |
| Adjusted Weighted Average Shares | 10.2M | 7.4M | 6.8M |
| Shares Issued Advanced Amortized For Deferred IPO Costs | 914.9K | 914.9K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Repayments Of Borrowings Classified As Financing Activities | $237.8K | $196.8K | $75.0K |
| Other Income | $1.5K | $4.0K | $96.2K |
| Other Gains Losses | -$68.7K | -$65.0K | -$33.3K |
| Interest Paid Classified As Operating Activities | $97.7K | $82.8K | $57.3K |
| Gains Losses On Change In Value Of Foreign Currency Basis Spreads Net Of Tax | $15.7K | -$516.00 | $640.00 |
| Finance Income Cost | -$95.9K | -$82.3K | -$23.0K |
| Finance Income | $1.7K | $474.00 | $219.00 |
| Finance Costs | $97.7K | $82.8K | $23.2K |
| Adjustments For Due To Related Parties Net | -$95.9K | $171.4K | $127.2K |
| Adjustments For Depreciation And Amortisation Expense | $75.8K | $64.2K | $74.0K |
| Adjustments For Decrease Increase In Inventories | -$378.2K | $742.0K | $191.2K |
| Longterm Borrowings | $1.5M | $1.1M | |
| Inventories | $560.0K | $933.3K | |
| Additional Paidin Capital | $3.5M | $3.0M | |
| Stock Issued During Period Value Class B Capital Injection | $300.0K | $500.0K | |
| Shortterm Borrowings | $34.7K | ||
| Repayment Of Loan To Related Parties Financing Activities | $1.3M | $701.7K | $648.0K |
Most recent annual filing with the SEC: August 14, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.